Artesunate/pyronaridine: Difference between revisions
Coopstudent (talk | contribs) →Medical uses: updated citation 4 |
Coopstudent (talk | contribs) →Medical uses: updated citation 4 |
||
| Line 51: | Line 51: | ||
Artesunate/pyronaridine is used for [[malaria]] of both the ''[[P. falciparum]]'' and ''[[P. vivax]]'' types.<ref name=WHO2010/> It is not recommended for severe disease.<ref name=EMA2017/> |
Artesunate/pyronaridine is used for [[malaria]] of both the ''[[P. falciparum]]'' and ''[[P. vivax]]'' types.<ref name=WHO2010/> It is not recommended for severe disease.<ref name=EMA2017/> |
||
A 2014 review found that the combination compared well to [[artemether/lumefantrine]].<ref>{{Cite journal|last=Pryce|first=Joseph|last2=Hine|first2=Paul|date=01 08, 2019|title=Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria|url=https://www.ncbi.nlm.nih.gov/pubmed/30620055|journal=The Cochrane Database of Systematic Reviews|volume=1|pages=CD006404|doi=10.1002/14651858.CD006404.pub3|issn=1469-493X|pmc=PMCPMC6353203|pmid=30620055}}</ref> Benefits also appear similar to [[mefloquine]] together with [[artesunate]].<ref name=" |
A 2014 review found that the combination compared well to [[artemether/lumefantrine]].<ref name=":0">{{Cite journal|last=Pryce|first=Joseph|last2=Hine|first2=Paul|date=01 08, 2019|title=Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria|url=https://www.ncbi.nlm.nih.gov/pubmed/30620055|journal=The Cochrane Database of Systematic Reviews|volume=1|pages=CD006404|doi=10.1002/14651858.CD006404.pub3|issn=1469-493X|pmc=PMCPMC6353203|pmid=30620055}}</ref> Benefits also appear similar to [[mefloquine]] together with [[artesunate]].<ref name=":0" /> It is not recommended for the prevention of malaria.<ref name=EMA2017/> |
||
==References== |
==References== |
||
Revision as of 15:32, 27 May 2019
| Combination of | |
|---|---|
| Artesunate | Antimalarial |
| Pyronaridine | Antimalarial |
| Clinical data | |
| Trade names | Pyramax[1] |
| Other names | Artesunate/pyronaridine tetraphosphate[1] |
| Routes of administration | By mouth[2] |
| ATC code | |
Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed dose combination medication for the treatment of malaria.[3][1] It can be used for malaria of both the P. falciparum and P. vivax types.[1] It combines artesunate and pyronaridine.[3] It is taken by mouth.[2]
The combination is generally well tolerated.[1] Side effects may include headache, vomiting, or cough.[1] Use in those with severe liver disease or kidney disease is not recommended.[2] Use is not generally recommended in early pregnancy.[2] However, there are no other options and if treatment may save the mother's life it may be used.[2] The two components work by different mechanisms.[2]
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] In 2010 the wholesale cost of a course of treatment in the developing world was between 0.55 and 2.18 USD.[1]
Medical uses
Artesunate/pyronaridine is used for malaria of both the P. falciparum and P. vivax types.[1] It is not recommended for severe disease.[2]
A 2014 review found that the combination compared well to artemether/lumefantrine.[4] Benefits also appear similar to mefloquine together with artesunate.[4] It is not recommended for the prevention of malaria.[2]
References
- ^ a b c d e f g h "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
- ^ a b c d e f g h "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Retrieved 13 December 2017.
- ^ a b c "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
- ^ a b Pryce, Joseph; Hine, Paul (01 08, 2019). "Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews. 1: CD006404. doi:10.1002/14651858.CD006404.pub3. ISSN 1469-493X. PMC PMCPMC6353203. PMID 30620055.
{{cite journal}}: Check|pmc=value (help); Check date values in:|date=(help)
